Peter Maag, Kyverna Therapeutics CEO

Kyver­na Ther­a­peu­tics adds $60M to the bank as it pre­pares to show­case ear­ly CAR-T da­ta in lu­pus nephri­tis

Kyver­na Ther­a­peu­tics’ an­ti-CD19 CAR-T is draw­ing new in­vestors to lead a $60 mil­lion in­fu­sion, re­load­ing as it steers through ear­ly clin­i­cal tri­als in au­toim­mune dis­eases.

Bain Cap­i­tal Life Sci­ences and Gor­don­MD Glob­al In­vest­ments led the Se­ries B ex­ten­sion, which brought the round to $145 mil­lion.

Emeryville, CA-based Kyver­na counts it­self among the first wave of drug de­vel­op­ers re­pur­pos­ing CAR-T ther­a­pies — which have made waves in can­cer — to treat au­toim­mune dis­eases, in hopes of tap­ping open a broad new field for cell ther­a­py. With tri­als open in both the US and Ger­many, Kyver­na said it cur­rent­ly has sev­en pa­tients in treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.